pravastatin has been researched along with Muscle Disorders in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (36.36) | 18.2507 |
| 2000's | 15 (45.45) | 29.6817 |
| 2010's | 6 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Barron, FE; Burridge, PW; Churko, JM; Diecke, S; Gold, JD; Gu, M; He, C; Hu, S; Kooreman, NG; Lee, J; Mordwinkin, NM; Ong, SG; Wu, H; Wu, JC | 1 |
| Barrett, DA; Bruce, KD; de Moor, CH; Eckel, RH; Gershkovich, P; Lee, JB; Sungelo, M; Taha, DA; Zgair, A | 1 |
| Abel, T; Fehér, J | 1 |
| Almagro, M; del Pozo, J; Fernández-Jorge, B; Fernández-Torres, R; Fonseca, E; Mazaira, M; Yebra-Pimentel, MT | 1 |
| Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D | 1 |
| Becker, DJ; Farrar, JT; French, B; Gordon, RY; Halbert, SC; Morris, PB; Rader, DJ; Schmitz, K; Thompson, PD | 1 |
| Gardberg, M; Kohonen, Ia; Lähdesmäki, J; Martikainen, MH | 1 |
| Kantola, I; Porela, P | 1 |
| Gotto, AM | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Chiba, K; Hosokawa, M; Morimoto, K; Oishi, T; Ueda, M; Ueda, S | 1 |
| Freedman, DB; Housley, D | 1 |
| Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Baker, SK; Isackson, PJ; Peltier, WL; Tarnopolsky, MA; Vladutiu, GD | 1 |
| Balestrieri, GP; Cerudelli, B; Giustina, G; Marocolo, D; Scalvini, T; Sleiman, I | 1 |
| Tobert, JA | 2 |
| Fujiyama, J; Kuriyama, M; Osame, M; Tokimura, Y; Utatsu, Y | 1 |
| Fukami, M; Fukushige, J; Kogure, Y; Maeda, N; Ogawa, T; Shimada, Y; Tsujita, Y | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T | 1 |
| Fujiyama, J; Higuchi, I; Kuriyama, M; Nakagawa, H; Nakahara, K; Osame, M; Sonoda, Y; Yoshidome, H | 1 |
| Chichibu, K; Inazu, A; Kajinami, K; Kiyohar, T; Koizumi, J; Mabuchi, H | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Bottorff, M; Worz, CR | 1 |
| Braunwald, E; Byington, RP; Cobbe, SM; Davis, BR; Friedman, CP; Keech, A; Pfeffer, MA; Sacks, FM; Tonkin, A | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; Kari, PH; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ; Vyas, KP | 1 |
| Kubo, M; Matsuzawa, Y; Miki, H; Nakamura, T; Takemura, K; Tarui, S | 1 |
2 review(s) available for pravastatin and Muscle Disorders
| Article | Year |
|---|---|
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
Topics: Aged; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Enzyme Inhibitors; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Isoenzymes; Itraconazole; Lovastatin; Male; Middle Aged; Muscular Diseases; Pravastatin; Rhabdomyolysis; Simvastatin | 2001 |
2 trial(s) available for pravastatin and Muscle Disorders
| Article | Year |
|---|---|
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2009 |
Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Topics: Aged; Biological Products; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Life Style; Male; Middle Aged; Muscle Strength; Muscular Diseases; Pravastatin; Recurrence; Treatment Outcome | 2010 |
29 other study(ies) available for pravastatin and Muscle Disorders
| Article | Year |
|---|---|
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.
Topics: Analysis of Variance; Animals; Apoptosis; Cell Differentiation; Diet, High-Fat; Endothelial Cells; Enzyme Inhibitors; Fibroblasts; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Injections, Intramuscular; Ischemia; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Diseases; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Random Allocation; Reperfusion Injury; Signal Transduction | 2015 |
Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity.
Topics: Acidosis; Adult; Animals; Cell Line; Chylomicron Remnants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Male; Mice; Models, Biological; Muscular Diseases; Pravastatin; Simvastatin | 2017 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Skin ulcers and myopathy associated with pravastatin therapy.
Topics: Aged; Anticholesteremic Agents; Drug Eruptions; Ear Diseases; Ear, External; Humans; Male; Muscular Diseases; Pravastatin; Skin Ulcer | 2009 |
Statin-induced myopathy in a patient with previous poliomyelitis.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Postpoliomyelitis Syndrome; Pravastatin | 2013 |
[Hypothyroidism, pravastatin therapy and myopathy].
Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypothyroidism; Middle Aged; Muscular Diseases; Pravastatin | 2002 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
Safety and statin therapy: reconsidering the risks and benefits.
Topics: Anticholesteremic Agents; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Meta-Analysis as Topic; Muscular Diseases; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyolysis; Transaminases; Treatment Outcome | 2003 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.
Topics: Alleles; DNA; DNA Primers; Exons; Humans; Introns; Japan; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Mutation; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Gitelman's syndrome presenting as intolerance to statin therapy.
Topics: Adult; Amiloride; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypokalemia; Kidney Diseases; Magnesium; Muscular Diseases; Pain; Potassium; Pravastatin; Spironolactone; Syndrome | 2005 |
Muscle symptoms associated with statins: a series of twenty patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin | 2006 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
Metabolic myopathies discovered during investigations of statin myopathy.
Topics: Aged; Alleles; Creatine Kinase; DNA; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Diseases; Middle Aged; Muscular Diseases; Mutation; Neurologic Examination; Pravastatin; Protein Prenylation; Pyridines | 2008 |
Pravastatin-associated myopathy. Report of a case.
Topics: Acute Disease; Aged; Biopsy; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Hypertension; Male; Muscle, Skeletal; Muscular Diseases; Myositis; Pravastatin | 1995 |
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
Topics: Drug Combinations; Drug Interactions; Follow-Up Studies; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1995 |
Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
Topics: Adult; Apolipoproteins; Brain Diseases; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Drug Therapy, Combination; Electrophysiology; Humans; Lipids; Lipoproteins; Male; Middle Aged; Muscular Diseases; Phytosterols; Pravastatin; Tendons; Xanthomatosis | 1994 |
Lovastatin and myopathy.
Topics: Drug Synergism; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1994 |
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
Topics: Administration, Oral; Animals; Cholesterol; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lovastatin; Male; Muscles; Muscular Diseases; Pravastatin; Rabbits; Simvastatin; Ubiquinone | 1993 |
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane | 1997 |
Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.
Topics: Animals; Cholesterol; Creatine Kinase; Electromyography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Diseases; Myotonia; Necrosis; Phospholipids; Pravastatin; Rabbits; Simvastatin; Tissue Distribution; Ubiquinone | 1998 |
Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
Topics: Achilles Tendon; Adult; Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Muscular Diseases; Pravastatin; Probucol; Tomography, X-Ray Computed; Treatment Outcome; Triglycerides; Xanthomatosis | 1999 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cohort Studies; Comorbidity; Demography; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Liver Diseases; Male; Middle Aged; Multivariate Analysis; Muscular Diseases; Pravastatin; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk; Risk Assessment; Time | 2002 |
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Topics: Animals; Anticholesteremic Agents; Cyclosporine; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Muscular Diseases; Necrosis; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Structure-Activity Relationship | 1992 |
Pravastatin and simvastatin for hypercholesterolemia.
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Muscular Diseases; Naphthalenes; Pravastatin; Simvastatin | 1991 |
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Topics: Animals; Biliary Tract; Cholestasis; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Microsomes, Liver; Muscular Diseases; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin | 1991 |
Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Topics: Adult; Anticholesteremic Agents; Bile Acids and Salts; Brain Diseases; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Muscular Diseases; Naphthalenes; Pravastatin; Tendons; Xanthomatosis | 1991 |